PDGFRA Exon 18 Mutation

CI-VAR-00000998Explore in graph →CIViC 2623

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor3
KIT Exon 11 Mutation OR KIT Exon 9 Mutation OR PDGFRA Exon 18 Mutation	Sorafenib	Predictive	B	Supports Sensitivity Response	2	submitted	EID11327 In this phase II study, 31 patients with histologically confirmed, metastatic GIST who failed after previous treatments involving both imatinib and sunitinib were enrolled. Tumour samples from 20 of t… (full text at CIViC) PMID 22270258 · Park et al., 2012 · Open in CIViC	civic
PDGFRA Exon 18 Mutation	Avapritinib	Predictive	A	Supports Sensitivity Response	3	submitted	EID7809 In phase I NAVIGATOR trial (NCT02508532) took part 43 patients with GIST harboring a PDGFRA exon 18 mutation, including 38 patients with PDGFRA D842V mutation.For patients harboring a PDGFRA exon 18 … (full text at CIViC) PMID 30274985 · Gebreyohannes et al., 2019 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.